Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avanir

This article was originally published in The Tan Sheet

Executive Summary

Docosanol 10% cream NDA (20-941) deemed "approvable" by FDA in May 30 letter. Final approval is expected in the third quarter after minor labeling issues are worked out, Avanir President and CEO Gerald Yakatan, PhD, says during a June 1 conference call. A proposed Rx version of the cream initially was determined "not approvable" by FDA due to missing data from a European trial and labeling concerns. The cold sore product will be marketed by SmithKline Beecham under a licensing agreement with San Diego-based Avanir. The introduction of the docosanol cream, expected to occur roughly six months after labeling is approved, will give SB another avenue into the OTC market. So far, SB has been unsuccessful in its attempts to switch its Rx cold sore drug Denavir (penciclovir) to OTC status

You may also be interested in...



Avanir Abreva Cold Sore/Fever Blister Cream Approved By FDA

Avanir Pharmaceuticals' 10% docosanol cream was approved July 25 for the treatment of cold sores and fever blisters. The product, which FDA's approval letter indicates will be marketed as Abreva Cream, will be the first FDA-approved OTC cold sore and fever blister treatment.

Avanir Abreva Cold Sore/Fever Blister Cream Approved By FDA

Avanir Pharmaceuticals' 10% docosanol cream was approved July 25 for the treatment of cold sores and fever blisters. The product, which FDA's approval letter indicates will be marketed as Abreva Cream, will be the first FDA-approved OTC cold sore and fever blister treatment.

Avanir Abreva Cold Sore/Fever Blister Cream Approved By FDA

Avanir Pharmaceuticals' 10% docosanol cream was approved July 25 for the treatment of cold sores and fever blisters. The product, which FDA's approval letter indicates will be marketed as Abreva Cream, will be the first FDA-approved OTC cold sore and fever blister treatment.

Topics

UsernamePublicRestriction

Register

PS091274

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel